# A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07256782/  
OnCo record `nct07256782` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of QLC5508, QL1706, Carboplatin, Cisplatin, QL2107 and Fluorouracil (5-FU) in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07256782 by Qilu Pharmaceutical Co., Ltd., with 444 participants planned, started 2025-10-24 and due to reach its primary completion in 2026-10. Interventions recorded: QLC5508, QL1706, Cisplatin/ Carboplatin, QL2107, Paclitaxel and 5-fluorouracil (5-FU).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07256782
- Phase: 1/2
- Setting: A Phase Ib/II, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of QLC5508 in Combination With Other Anti-tumor Agents in Patients With Advanced Solid Tumors
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 444

## Sources

- ClinicalTrials.gov NCT07256782: https://clinicaltrials.gov/study/NCT07256782

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [QL1706](https://onco.cc/drugs/ql1706/), [QL2107](https://onco.cc/drugs/ql2107/), [QLC5508](https://onco.cc/drugs/qlc5508/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct07256782.json